Sobera on science-focused secondaries

Few firms invest in biotech and life sciences secondaries because it can be difficult to evaluate the portfolios, says Johannes Rabini, managing director of Berlin-based Sobera Capital.

To view this content you must sign in:

Not yet registered? Join today to access Secondaries Investor's industry insights and updates.